Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

Table 1 Patient baseline characteristics (n = 36)

Variable	Overall
Age	52 (12)
Sex
Male	12 (33 %)
Female	24 (67 %)
Stage
IVa	4 (11 %)
IVb	2 (6 %)
IVc	30 (83 %)
Primary site
Cutaneous	28 (78 %)
Acral	4 (11 %)
Mucosal	0 (0 %)
Unknown	4 (11 %)
Treatment
Dabrafenib + trametinib	34 (94 %)
Dabrafenib	2 (6 %)
Vemurafenib	0 (0 %)
Re-challenge dabrafenib + trametinib^a	8 (22 %)
First plasma sample
Before initiation of targeted therapy	16 (44 %)
After initiation of targeted therapy	20 (56 %)

Data are mean (SD) or n (%).
Baseline characteristics at the moment of collection of the first plasma sample
^aEight patients were treated with dabrafenib and trametinib after documentation of disease progression at least 12 weeks following the last day of dosing of a BRAF-inhibitor containing treatment regimen (ClinicalTrials.gov Identifier:NCT02296996)

ISSN: 1479-5876